In addition, various other cancers, including pancreatic ductal adenocarcinoma, non-small cell lung cancer (NSCLC), and melanoma, frequently show cyclin D1 overexpression and amplification, which emphasizes the potential use of CDK4/6 inhibitors in their treatment [9,10]. This evidence concerns the gene CCND1 and cancer.